Lavipharm S.A. Share Price

LAVI

GRS246003008

Pharmaceuticals

Delayed Athens S.E. 08:41:47 02/10/2026 BST			5-day change	1st Jan Change
1.580 ^EUR	+1.94%		+0.64%	+62.89%

09-17	Lavipharm S.A. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
06-24	Lavipharm S.A. announces Annual dividend, payable on July 24, 2026	CI

Lavipharm SA is a Greece-based pharmaceutical and healthcare company engaged in the research and development of drug delivery solutions and the commercialisation of pharmaceutical, over-the-counter (OTC) and related healthcare products. It is active in the provision of prescription medicines, OTC products and food supplements, supported by integrated activities across research and development, manufacturing and commercial operations. It maintains a portfolio focused primarily on therapeutic areas including cardiology, central nervous system disorders, urology, oncology and chronic pain, supplying solutions designed for healthcare professionals and patients. The Company operates in both domestic and international markets and combines product development capabilities with market access and distribution activities, while acting as the parent entity of the Lavipharm Group through which its broader operations are conducted.

Employees

306

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
02/10/26	€1.580	+1.94%	3,055
01/10/26	€1.550	-1.52%	14,315
30/09/26	€1.574	+0.25%	12,795
29/09/26	€1.570	+0.13%	16,420
28/09/26	€1.568	-0.13%	34,549

Delayed Quote Athens S.E.

More quotes

Stock Market
Stocks
LAVI Stock

As early as today, start finding the best investment opportunities!

Market Cap	265M 298M 248M 226M 425M 28.69B 431M 2.99B 1.16B 14.61B 1.12B 1.09B 46.94B	P/E 2024	14.9x	P/E 2025	27.9x
Enterprise Value	291M 328M 272M 248M 467M 31.59B 474M 3.3B 1.28B 16.09B 1.23B 1.2B 51.67B	EV / Sales 2024	3.07x	EV / Sales 2025	3.04x
Free-Float	38.91%	Yield 2024	2.52%	Yield 2025	2.06%

09-17	Lavipharm S.A. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
06-24	Lavipharm S.A. announces Annual dividend, payable on July 24, 2026	CI
05-28	Lavipharm Q1 earnings before tax from continuing operations EUR1.41 million, up 28.6% Y/Y	RE
05-28	Lavipharm S.A. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-09	Lavipharm to acquire Durogesic pain patch rights from Janssen for $12.0 million	RE
03-19	Lavipharm SA FY 2025 earnings after tax EUR 6.0 million versus EUR 9.0 million year ago	RE
03-19	Lavipharm S.A. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
11-17	Lavipharm 9-month net profit down to EUR 3.5 million	RE
18/09/25	Lavipharm H1 adjusted EBITDA at EUR 7.7 million, up 29.4% Y/Y	RE
17/09/25	Lavipharm S.A. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
02/07/25	Lavipharm S.A. announces Annual dividend, payable on July 24, 2025	CI
15/05/25	Lavipharm Q1 Net Profit At EUR 1.6 Million, Up 46.8% YoY	RE
14/04/25	Lavipharm And Tikun Olam Europe Launch Joint Telemedicine Company	RE

10-01	Lavipharm S A : Announcement	PU
09-03	Lavipharm S A : Announcement Appointment of Chief Manufacturing & Operations Officer	PU
06-11	Lavipharm S A : Announcement Appointment of Chief Quality Officer	PU
05-22	Lavipharm S A : IMPORTANT CORPORATE EVENTS	PU
11-07	Lavipharm S A : OTHER ANNOUNCEMENTS	PU

1 day	+1.94%
1 week	+0.64%
Current month	+0.38%
1 month	-2.59%
3 months	+3.95%
6 months	+29.93%
Current year	+62.89%

1 week	1.54	1.59
1 month	1.53	1.64
Current year	0.94	1.74
1 year	0.76	1.74
3 years	0.58	1.74
5 years	0.35	2.22
10 years	0.21	2.22

Lavipharm S.A. Share Price

Stocks

LAVI

GRS246003008

Pharmaceuticals

Valuation: Lavipharm S.A.

Chart: Lavipharm S.A.

Latest news: Lavipharm S.A.

Press Releases: Lavipharm S.A.

Quotes and Performance

Price Extremes

Managers and Directors: Lavipharm S.A.

Latest insider transactions

Generic Pharmaceuticals

Financials

Company Profile

Quotes

Manager	Title	Age	Since
Vassilis Baloumis DFI	Director of Finance/CFO	-	30/11/2021
Ligia Panaitescu CTO	Chief Tech/Sci/R&D Officer	-	-
Eleana Nikolopoulou CMP	Compliance Officer	-	-

Director	Title	Age	Since
Venetsiana-Loukia Lavida BRD	Director/Board Member	-	-
Christos Panagiotis Diamantopoulos BRD	Director/Board Member	76	-
Minas G. Tanes CHM	Chairman	86	31/12/2020

Date	Insider	Type	Main position	Quantity	% Market Cap.
12/02/25	Vassilis Baloumis	Buy	Chief Financial Officer	20,000	0.0119%
27/05/23	Thomas Tseronis	Sell		35,434	0.0189%
28/03/23	Vassilis Baloumis	Buy	Chief Financial Officer	23,455	0.0125%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
LAVIPHARM S.A.	+1.94%	+0.64%	+95.06%	+133.73%	298M
ELI LILLY AND COMPANY	-0.62%	-2.71%	+39.30%	+114.07%	1,025B
JOHNSON & JOHNSON	-2.30%	-4.44%	+39.03%	+66.07%	623B
ABBVIE INC.	-0.63%	-1.96%	+6.36%	+74.38%	459B
MERCK & CO., INC.	-1.03%	-2.82%	+59.56%	+39.69%	355B
ROCHE HOLDING AG	-0.40%	-3.77%	+21.95%	+39.77%	336B
NOVARTIS AG	+0.27%	-1.35%	+13.61%	+26.57%	270B
ASTRAZENECA PLC	+0.28%	-4.17%	-3.42%	+9.84%	247B
AMGEN INC.	-3.38%	+0.30%	+36.44%	+51.54%	220B
GILEAD SCIENCES, INC.	-1.04%	-1.46%	+32.70%	+96.82%	183B
Average	-0.70%	-1.88%	+34.06%	+65.25%	371.85B
Weighted average by Cap.	-0.99%	-2.11%	+30.36%	+69.49%

	2024	2025
Net sales	52.95M 59.61M 49.51M 45.12M 84.95M 5.74B 86.11M 599M 232M 2.92B 224M 219M 9.39B	62.58M 70.46M 58.53M 53.33M 100M 6.78B 102M 708M 274M 3.46B 265M 259M 11.1B
Net income	8.98M 10.11M 8.4M 7.65M 14.41M 974M 14.61M 102M 39.34M 496M 37.97M 37.14M 1.59B	5.99M 6.74M 5.6M 5.1M 9.6M 649M 9.74M 67.72M 26.22M 330M 25.3M 24.75M 1.06B
Net Debt	28.34M 31.9M 26.5M 24.15M 45.46M 3.07B 46.09M 321M 124M 1.56B 120M 117M 5.02B	26.67M 30.03M 24.94M 22.73M 42.79M 2.89B 43.38M 302M 117M 1.47B 113M 110M 4.73B